S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
S&P 500   3,122.03 (+0.05%)
DOW   28,036.22 (+0.11%)
QQQ   203.07 (+0.08%)
AAPL   267.10 (+0.50%)
FB   197.40 (+1.18%)
MSFT   150.34 (+0.25%)
GOOGL   1,319.84 (-1.03%)
AMZN   1,752.53 (+0.75%)
CGC   14.22 (-7.24%)
NVDA   212.28 (+3.96%)
MU   47.82 (+0.23%)
BABA   184.61 (-0.47%)
GE   11.44 (-0.69%)
TSLA   349.99 (-0.62%)
T   39.63 (+0.33%)
AMD   39.88 (+3.42%)
ACB   2.28 (-16.48%)
F   8.95 (+0.00%)
PRI   131.10 (+0.37%)
NFLX   302.57 (+2.56%)
BAC   32.96 (+0.09%)
GILD   64.29 (-1.20%)
DIS   147.65 (+2.06%)
Log in

GlycoMimetics Stock Price, Forecast & Analysis (NASDAQ:GLYC)

$5.72
-0.50 (-8.04 %)
(As of 11/18/2019 04:00 PM ET)
Today's Range
$5.65
Now: $5.72
$6.24
50-Day Range
$4.16
MA: $5.05
$6.59
52-Week Range
$2.64
Now: $5.72
$13.56
Volume263,000 shs
Average Volume438,594 shs
Market Capitalization$248.02 million
P/E RatioN/A
Dividend YieldN/A
Beta2.74
GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLYC
CUSIPN/A
Phone240-243-1201

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20,000.00
Price / Sales12,400.96
Book Value$3.85 per share

Profitability

Net Income$-48,270,000.00

Miscellaneous

Employees50
Market Cap$248.02 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive GLYC News and Ratings via Email

Sign-up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.


GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

How were GlycoMimetics' earnings last quarter?

GlycoMimetics Inc (NASDAQ:GLYC) posted its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.08. View GlycoMimetics' Earnings History.

When is GlycoMimetics' next earnings date?

GlycoMimetics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for GlycoMimetics.

What price target have analysts set for GLYC?

6 analysts have issued twelve-month target prices for GlycoMimetics' stock. Their forecasts range from $5.00 to $18.00. On average, they expect GlycoMimetics' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 74.8% from the stock's current price. View Analyst Price Targets for GlycoMimetics.

What is the consensus analysts' recommendation for GlycoMimetics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GlycoMimetics.

What are Wall Street analysts saying about GlycoMimetics stock?

Here are some recent quotes from research analysts about GlycoMimetics stock:
  • 1. According to Zacks Investment Research, "GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. " (10/9/2019)
  • 2. HC Wainwright analysts commented, "We base our $23 price target on probability-adjusted forecasts for uproleselan in AML as well as rivipansel in SCD VOC. We use the net present value of our revenue forecast through 2027, apply a 60% POS for AML and a 70% POS for SCD 4x price/sales multiple for AML, and estimated 2019 year-end net cash of $3.11 per share, to arrive at our price target. Our P/S multiple of 4x is inline with GlycoMimetics’ peers that range between 2-5x." (4/12/2019)

Has GlycoMimetics been receiving favorable news coverage?

Media headlines about GLYC stock have been trending very negative recently, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. GlycoMimetics earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for GlycoMimetics.

Are investors shorting GlycoMimetics?

GlycoMimetics saw a decline in short interest in October. As of October 15th, there was short interest totalling 3,620,000 shares, a decline of 6.7% from the September 15th total of 3,880,000 shares. Based on an average daily volume of 867,000 shares, the days-to-cover ratio is currently 4.2 days. Approximately 10.9% of the company's shares are sold short. View GlycoMimetics' Current Options Chain.

Who are some of GlycoMimetics' key competitors?

What other stocks do shareholders of GlycoMimetics own?

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the folowing people:
  • Ms. Rachel K. King, Pres, CEO & Director (Age 60)
  • Mr. Brian M. Hahn, Sr. VP, CFO & Sec. (Age 45)
  • Dr. John L. Magnani, Sr. VP of Research, Chief Scientific Officer & Director (Age 66)
  • Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 51)
  • Mr. Henry Flanner, VP of Technical Operations

Who are GlycoMimetics' major shareholders?

GlycoMimetics' stock is owned by many different of institutional and retail investors. Top institutional investors include Alps Advisors Inc. (0.20%), Prentiss Smith & Co. Inc. (0.04%), Tower Research Capital LLC TRC (0.03%) and California Public Employees Retirement System (0.02%). Company insiders that own GlycoMimetics stock include Brian M Hahn, Bvf Partners L P/Il, Daniel M Junius, Helen M Thackray, John L Magnani and M James Barrett. View Institutional Ownership Trends for GlycoMimetics.

Which institutional investors are selling GlycoMimetics stock?

GLYC stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc.. View Insider Buying and Selling for GlycoMimetics.

Which institutional investors are buying GlycoMimetics stock?

GLYC stock was bought by a variety of institutional investors in the last quarter, including Prentiss Smith & Co. Inc., Tower Research Capital LLC TRC and California Public Employees Retirement System. Company insiders that have bought GlycoMimetics stock in the last two years include Bvf Partners L P/Il and Daniel M Junius. View Insider Buying and Selling for GlycoMimetics.

How do I buy shares of GlycoMimetics?

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $5.72.

How big of a company is GlycoMimetics?

GlycoMimetics has a market capitalization of $248.02 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-48,270,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. GlycoMimetics employs 50 workers across the globe.View Additional Information About GlycoMimetics.

What is GlycoMimetics' official website?

The official website for GlycoMimetics is http://www.glycomimetics.com/.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]


MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  273 (Vote Outperform)
Underperform Votes:  232 (Vote Underperform)
Total Votes:  505
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe GLYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel